Last year, Belgium’s ExeVir Bio raised 23 million euros ($27 million) to finance development of llama antibodies – and now it is ready to begin clinical development of a potential treatment ...

Belgium’s ExeVir Bio is to accelerate development of a new treatment for COVID-19 based on llama antibodies, after a 23 million euro ($27 million) financing round. ExeVir is a spin-out of Vlaams ...

He described the process similar to that of microscopic Velcro hooks; whereby, one hook is the viral protein and the other is the llama antibody. "If you consider one viral protein binding to one ...

ImmunoPrecise provides a range of services that includes antibody discovery in wild-type and transgenic mouse, rat and chicken models, rabbit and llama monoclonal antibodies (mAbs), and custom and ...